


Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells

Graphical Abstract



Authors

Seth D. Reighard, Stacey A. Cranert, Kelly M. Rangel, ..., David F. Smith, Hermine I. Brunner, Stephen N. Waggoner

Correspondence

stephen.waggoner@cchmc.org

In Brief

Exaggerated follicular helper T cell (T_{FH}) responses promote autoimmunity and other pathologies, yet clinical tools to specifically target T_{FH} are lacking. Reighard et al. describe programmed death-ligand 1 (PD-L1)-based chimeric antigen receptor-expressing human natural killer cells that selectively eliminate human T_{FH} *in vitro* and in humanized mice based on the high expression of PD-1 by the targeted T_{FH} cells.

Highlights

- T_{FH} exhibit high expression levels of PD-1
- PD-L1 CAR-expressing NK cells selectively kill T_{FH} but not Treg or memory T cells
- Killing of T_{FH} by CAR NK inhibits B cell proliferation and antibody production
- The PD-L1 CAR represents a novel therapeutic tool in T_{FH}-driven diseases



Report

Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells

Seth D. Reighard,^{1,2,3} Stacey A. Cranert,^{1,13} Kelly M. Rangel,^{1,4} Ayad Ali,^{1,2,3} Ivayla E. Gyurova,^{1,5} Arthur T. de la Cruz-Lynch,¹ Jasmine A. Tuazon,^{1,14} Marat V. Khodoun,^{6,7} Leah C. Kottyan,^{1,2,3,4,8} David F. Smith,^{8,9,10,11} Hermine I. Brunner,^{8,12} and Stephen N. Waggoner^{1,2,3,5,8,15,*}

¹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

²Medical Scientist Training Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

³Immunology Graduate Training Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

⁴Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

⁵Pathobiology and Molecular Medicine Graduate Program, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

⁶Division of Immunology, Allergy, and Rheumatology, Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA

⁷Department of Research, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220, USA

⁸Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

⁹Division of Pediatric Otolaryngology - Head & Neck Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

¹⁰Division of Pulmonary and Sleep Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

¹¹Department of Otolaryngology - Head & Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA

¹²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA

¹³Present address: Poseida Therapeutics, San Diego, CA 92121, USA

¹⁴Present address: Medical Scientist Training Program, The Ohio State University College of Medicine, Columbus, OH 43210, USA

¹⁵Lead Contact

*Correspondence: stephen.waggoner@cchmc.org

<https://doi.org/10.1016/j.xcrm.2020.100003>

SUMMARY

Follicular helper T cells (T_{FH}) are critical for vaccine and infection elicitation of long-lived humoral immunity, but exaggerated T_{FH} responses can promote autoimmunity and other pathologies. It is unfortunate that no clinical interventions exist for the selective depletion of follicular T cells to alleviate these diseases. We engineered a chimeric antigen receptor (CAR) facilitating the specific targeting of cells with high expression levels of human programmed cell death protein 1 (PD-1), a cardinal feature of follicular T cells. CAR-expressing human natural killer (NK) cells robustly and discriminately eliminated PD-1^{high} follicular human T cells *in vitro* and in a humanized mouse model of lupus-like disease while sparing B cells and other PD-1^{low} T cell subsets, including regulatory T cells. These results establish a strategy for specific targeting of PD-1^{high} T cells that can be advanced as a clinical tool for the selective depletion of pathogenic follicular T cells or other PD-1^{high} target cells in certain disease states.

INTRODUCTION

Follicular helper CD4⁺ T cells (T_{FH}) are key players in the humoral immune response. T_{FH} are phenotypically defined by the transcription factor B cell lymphoma 6 protein (BCL6) and by the high cell-surface expression levels of C-X-C motif chemokine receptor 5 (CXCR5), inducible co-stimulator (ICOS), and programmed cell death protein 1 (PD-1).¹ Activated and differentiated T_{FH} migrate into B cell follicles and aid in germinal center (GC) formation, maintenance, and function.² In fact, T_{FH} in the GC provide crucial signals for proliferation, isotype class switching, affinity maturation, and terminal differentiation of responding B cells.³ These functional contributions highlight the potent role

of T_{FH} in the generation of lifelong protective humoral immunity following infection or immunization. Despite these benefits, exaggerated or dysregulated T_{FH} functions can contribute to severe disease.

Aberrant T_{FH} responses are associated with the development and persistence of pathogenic autoantibody-secreting cells in a variety of autoimmune diseases.^{4–6} These include Sjögren syndrome, juvenile dermatomyositis, multiple sclerosis, type 1 diabetes mellitus, rheumatoid arthritis, and systemic lupus erythematosus (SLE). Patients with SLE harbor increased T_{FH} numbers, particularly during disease flares.^{7,8} In fact, the number of circulating T_{FH} positively correlates with autoantibody titers in patients with SLE. Moreover, T_{FH} are not only necessary but also



sufficient to trigger SLE-like disease in select mutant mouse models of disease.^{9,10} Most SLE-like mouse models also demonstrate similar aberrant and pathogenic T_{FH} responses.⁵ T_{FH} are implicated in immunoglobulin E (IgE) production and potentially contribute to allergic disease.¹¹ In addition, certain subtypes of lymphoma, including angioimmunoblastic T cell lymphoma, demonstrate a T_{FH} phenotype.¹² Collectively, the established roles of T_{FH} in disease justify exploring therapeutic strategies that suppress pathogenic T_{FH} or selectively eliminate this cellular pool completely.

Therapeutics that target T_{FH} to potentially prevent, alleviate, or induce remission of chronic disease are not well developed. The present work is inspired by the clinical success of tumor-targeting chimeric antigen receptors (CARs) expressed by cytotoxic lymphocytes in the treatment of multiple types of human cancer.¹³ The use of CAR technology to selectively eliminate T_{FH} represents a promising solution to the relative dearth of clinical tools for the specific targeting of T_{FH} . CAR specificity for tumors is classically conferred by an antibody single-chain variable fragment (scFv) against a unique tumor surface antigen.¹⁴ The scFv-containing recognition domain is coupled to signaling domains such as CD28 and CD3 ζ that activate CAR-expressing lymphocytes and trigger an effective cytotoxic response against their tumor targets.

Although highly effective in eliminating certain neoplasms, CAR T cell therapy has significant risks that threaten its clinical utility.^{15,16} A substantial percentage of patients treated with CAR T cells have experienced toxic and even deadly side effects, including cytokine release syndrome (CRS), graft-versus-host disease (GVHD), and neurotoxicity. An emerging alternative to CAR T cells is CAR expression in natural killer (NK) cells.

Pilot studies suggest that CAR NK cells exert potent anti-leukemic activity,¹⁷ while maintaining a greatly enhanced safety profile in comparison to their CAR T cell counterparts.^{18,19} For example, early trials using CAR NK cells have shown minimal adverse effects and almost no reported CRS or neurotoxicity.^{19,20} Moreover, CAR NK cells generated from cord blood, stem cells, or cell lines can be used therapeutically in a safe manner, thereby elevating the “off-the-shelf” potential of CAR NK cell therapies and likely reducing manufacturing costs.^{17–19,21}

In this study, we engineered and evaluated an innovative CAR NK- cell that targets PD-1-expressing cells to eliminate T_{FH} . The extracellular portion of programmed death-ligand 1 (PD-L1) was used in place of an scFv to confer selectivity of the CAR NK cells for follicular T cells that express very high levels of surface PD-1. This finding establishes CAR NK cell targeting of PD-1 as a promising approach for therapeutic culling of follicular T cells that may be valuable in autoimmunity and other T_{FH} -driven disease states.

RESULTS

PD-1 Is a Selective Marker of Human Follicular T Cells

The *PDCD1* gene encoding PD-1 is expressed at low to intermediate levels on several types of leukocytes, but is highly expressed by T_{FH} .¹ In fact, T_{FH} (CD3⁺CD4⁺CXCR5⁺ICOS⁺) exhibit high PD-1 expression relative to other leukocyte subsets from non-inflamed human tonsil mononuclear cells (Figure 1A). The median fluorescence intensity (MFI) of PD-1 expression

on T_{FH} exceeded that of regulatory T cells (Treg, CD3⁺CD4⁺CD25⁺FoxP3⁺); naive (CD45RA⁺CD45RO⁻) or memory (CD45RA⁻CD45RO⁺) T cells (CD3⁺; CD4⁺ or CD8⁺); immature (CD21⁺CD38^{high}CD27⁻IgM⁺IgD⁻), mature (CD27⁻IgD⁺IgM⁺), memory (CD21⁺CD27⁺CD38⁻), and follicular (CD21⁺CD38^{low}CD27⁻IgD⁺IgM⁻) B cells (CD3⁻CD19⁺CD20⁺); plasmablasts (CD3⁻CD19⁺CD27⁺CD138⁺CD38^{high}); NK (CD45⁺CD3⁻CD56⁺) or NKT (CD45⁺CD3⁺CD56⁺) cells; classical (CD16⁻) and non-classical (CD16⁺) monocytes (CD45⁺CD3⁻CD19⁻CD14⁺); and dendritic cells (CD45⁺CD3⁻CD19⁻CD1c⁺HLA-DR⁺) in both human tonsil (Figure 1B) and peripheral blood mononuclear cells (PBMCs) (Figure 1C). PD-1 expression on tonsillar T_{FH} cells was only surpassed by the closely related, albeit >1,600-fold less abundant follicular regulatory T cell (T_{FR} , CD3⁺CD4⁺CXCR5⁺ICOS⁺CD25⁺Foxp3⁺) population (Figures 1A and 1B). Thus, follicular T cells demonstrated roughly a 6- to 600-fold higher PD-1 expression than other leukocytes.

PD-L1-Based CAR Generation and Expression on NK Cells

Selective targeting of PD-1^{high} T_{FH} cells may be achieved by optimizing the affinity of a CAR to limit its activation by PD-1^{low} cells. The anti-tumor antigen antibody-derived scFvs often used in CAR design typically confer a half-maximal effective concentration (EC₅₀) affinity of 0.015–320 nM, which facilitates the killing of targets exhibiting both high and low expression levels of the target protein.^{22,23} In contrast, the K_d affinity of PD-L1, also known as B7-H1 or CD274, for PD-1 is reported to be between 770 and 8,200 nM.^{24,25} Therefore, we reasoned that the lower affinity of PD-L1 for PD-1, relative to the scFv of an anti-PD-1 antibody, would permit more selective targeting of PD-1^{high} versus other PD-1^{low} bystander cells.

We cloned the extracellular domain of human PD-L1 (amino acids [aa] 19–238) upstream of conventional CAR components¹⁴ (Figure S1), into a lentiviral plasmid. Empty and PD-L1-CAR-containing plasmids were packaged in vesicular stomatitis virus glycoprotein-pseudotyped viral particles and subsequently used to transduce the human NK cell line NK-92, which is being used for immunotherapy.²⁶ Based on fluorescent reporter expression, transduction efficiency in NK-92 cells was 6.8% and 1.3% for the empty and CAR-encoding lentiviral vectors, respectively, as measured by flow cytometry (Figure S2A). After sorting for fluorescent reporter-positive cells, CAR transgene mRNA (Figure S2B) and surface PD-L1 (Figure S2C) were detected on CAR-transduced but not empty vector-transduced NK-92.

PD-L1 CAR NK Cells Are Activated by Plate-Bound Ligands

CAR NK-92 cells in short-term culture with either plate-bound antibody specific for PD-L1 (α -PD-L1) or recombinant human PD-1-Fc fusion protein (rhPD-1-Fc) triggered degranulation, as measured by surface exposure of CD107a (Figure 2A). This response was not observed in control NK-92 cells. Neither CAR nor control NK-92 responded to IgG-Fc fusion protein or Ig isotype (negative controls), while both CAR and control NK-92 responded robustly to stimulation with (positive control) phorbol myristate acetate (PMA) and ionomycin (Figure 2A).




Figure 1. PD-1 is a Selective Marker of Human Follicular T Cells

(A) Representative PD-1 expression levels determined by flow cytometry on electronically gated subsets of leukocytes in non-inflamed human tonsil. (B) Median PD-1 expression (median fluorescence intensity) across major leukocyte subsets identified in 2 independent non-inflamed human tonsils. (C) PD-1 expression across major leukocytes subsets identified in 3 healthy human PBMCs.

PD-L1 CAR NK Cells Selectively Kill T_{FR} Cells and Suppress T-Induced B Cell Responses

To test the function of PD-L1 CAR NK-92 cells in response to bona fide human T_{FR}, bulk CD4 T cells (including T_{FR}, T_{reg}, and Treg) were magnetically purified from non-inflamed human tonsil. Co-culture of tonsil CD4 T cells with CAR-expressing NK-92 for 4 h resulted in a >7-fold reduction in recoverable T_{FR} cells (CXCR5⁺PD-1^{high}) relative to cultures of CD4 T cells alone (Figure 3A). This was not observed when CD4 T cells were co-cultured with control NK-92 (Figure 3A). Correspondingly, remaining T_{FR} (CD45RO⁺CXCR5⁺PD-1^{high}) cells after culture with CAR NK-92 exhibited 9-fold more PI uptake than those cultured with control NK-92 or without added NK cells (Figure 3B), as well as enhanced Zombie viability dye staining (Figure 3C). Non-T_{FR} CD4 memory T cells (CD45RO⁺CXCR5⁺PD-1^{low}) exhibited some loss of viability when cultured with CAR NK-92, although overall PI uptake in this population was miniscule relative to that of T_{FR} cells (Figure 3B). Although present in trace quantities, gated T_{FR} (CD4⁺CXCR5⁺ICOS⁺CD25⁺CD127^{low}) cells demonstrated equal PI uptake when cultured with CAR or control NK cells (Figure 3B), thus complicating the interpretation of the susceptibility of T_{FR} to PD-L1 CAR-expressing cells. Naive (CD45RO⁻) CD4 T cells (Figure 3B) and Treg (CD4⁺Foxp3⁺CD25⁺CD127^{low}) cells (Figure 3D) demonstrated no such loss of viability over background after co-culture with either type of NK-92.

To determine the capacity of CAR NK cells to target T_{FR} in a more complex cellular milieu reminiscent of lymphoid follicles, we generated co-cultures of human tonsillar lymphocytes enriched for T_{FR} cells (CD19⁻CD3⁺CD4⁺CXCR5⁺) and memory B cells (CD3⁻CD19⁺CD27⁺) added in a 1:2 ratio, respectively. *Staphylococcal* enterotoxin B (SEB), which crosslinks the T cell receptor with major histocompatibility complex class II (MHC class II),²⁸ was added to these co-cultures to trigger mutual cell proliferation. At an effector (NK-92) to target (T_{FR}) ratio (E:T) of 5:1, CAR NK-92 demonstrated 12-fold more degranulation than control NK-92 (Figure 4A). Calcein-AM (acetoxymethyl)-labeled T_{FR} and B cells co-cultured with CAR-expressing but not control NK-92 released calcein into culture supernatant in an effector cell concentration-dependent manner (Figure 4B). PI staining of target lymphocytes revealed a greater loss of viability in T_{FR} cells cultured with CAR

Stimulation of CAR NK-92 over increasing concentrations of plate-bound rhPD-1-Fc (Figure 2B) revealed a response curve with an affinity of PD-L1 CAR NK-92 for rhPD-1-Fc with a calculated EC₅₀ of 0.61 μg/mL. These experimental findings establish that our PD-L1-based CAR construct was functional and responsive to ligands that bind PD-L1.

PD-L1 CAR NK Cells Respond to Cell-Associated PD-1 via Degranulation and Killing

The *Drosophila melanogaster*-derived S2 cell line lacks the expression of relevant activating or inhibitory receptors for human NK cells, and therefore elicits no functional NK cell response.²⁷ Consistent with these data, NK-92 cells did not degranulate when co-cultured with S2 cells, regardless of CAR expression (Figure 2C). In contrast, CAR NK-92 but not control NK-92 degranulated (Figure 2C) during co-culture with S2 cells engineered to express surface human PD-1 (Figure S3A). Moreover, CAR NK-92 cells degranulated 34% more (Figure 2D) during co-culture with sorted PD-1^{high} S2 cells (Figure S3B) than CAR NK-92 cell co-cultured with PD-1^{low} S2 cells. Similarly, Raji human B lymphoma cells engineered to express high levels of human PD-1 (Figure S3C) triggered 2.4-fold more degranulation of CAR NK-92 relative to degranulation in response to wild-type Raji cells (Figure 2E). PD-1⁺ Raji cells cultured in the presence of CAR NK-92, but not those cultured with control NK-92, exhibited uptake of propidium iodide (PI) as a measure of the loss of viability (Figure 2F). Furthermore, ⁵¹Cr-labeled PD-1⁺ Raji cells cultured with CAR NK-92 released more radioactive chromium into culture supernatant (in an effector cell concentration-dependent manner) than PD-1⁺ Raji cultured with control NK-92 (Figure 2G). Thus, CAR NK-92 recognize and respond to cell surface PD-1 expressed on otherwise NK cell refractory target cells.




Figure 2. PD-L1 CAR NK Cell Responses to Plate- and Cell-Associated PD-1

(A–C) Degranulation (surface exposure of CD107a) of control (left) or CAR (right) NK-92 following a 4-h incubation in the presence of (A) anti-PD-L1 IgG (20 μ g/mL, control: goat IgG) or rhPD-1-Fc (10 μ g/mL, control: IgG-Fc), (B) rhPD-1-Fc (displayed dose, control: IgG-Fc), or (C) PD-1⁺ *Drosophila* S2 cells (control: S2 cells) at an effector:target (E:T) ratio of 1:5. PMA/ionomycin used as positive control in (A) and (C).

(D) Fold degranulation (over control NK-92, dotted line) of CAR NK-92 in the presence of control, PD-1^{low}, or PD-1^{high} *Drosophila* S2 cells at 1:5 E:T for 4 h (n = 2–3).

(E) CAR NK-92 degranulation in the presence of control or PD-1⁺ Raji cells for 4 h at 1:5 E:T (n = 4).

(F) Control or PD-1⁺ Raji uptake of PI following 4-h co-culture with either control or CAR NK-92 at a 20:1 E:T (n = 2–3).

(G) Percentage lysis of ⁵¹Cr-labeled PD-1⁺ Raji cells after incubation with control or CAR NK-92 for 4 h at various E:T ratios.

Error bars in (B) and (G) denote standard deviations. Representative data from 1 of 2 (B and D–G) or 3 (A and C) experimental replicates are shown. Data analyzed via (D and F) 1-way ANOVA with multiple comparisons or (E) Student's t test.

See also [Figures S1–S3](#).

NK-92 cells compared to control NK-92 (Figure 4C). B cells, conversely, exhibited no increased PI uptake following the addition of either CAR-expressing or control NK-92 (Figure 4C). In a separate assay, we cultured enriched tonsillar CD4 T cells in the presence of control or CAR NK-92 for 4 h (followed by subsequent magnetic depletion of CD56⁺ NK cells), then co-cultured 3×10^4 residual CD4 T cells with autologous, CellTrace Violet (CTV)-labeled memory B cells (in a 1:2 ratio) in the presence of SEB. We observed less proliferation of memory B cells, a

decreased prevalence of plasmablasts, and less supernatant IgG in wells containing CD4 T cells pre-cultured with CAR NK-92 (Figure 4D). Similar findings were observed when CAR or control NK cells were added directly to co-cultures of tonsillar T_{FH} and memory B cells (Figure S4A). These results demonstrate that PD-L1 CAR-expressing NK-92 promotes the death of T_{FH} while sparing other lymphocyte populations. Consequently, this killing can suppress T_{FH}-mediated effects on memory B cells, including the production of Ig.




Figure 3. PD-L1 CAR NK Cells Selectively Kill T_{FH}

(A) Representative plots of enriched tonsillar CD4 T cells, with circles denoting gated T_{FH} ($CXCR5^+PD-1^+$) following a 4-h incubation either alone (left, $n = 1$) or in the presence of control NK-92 (middle, $n = 5$) or CAR NK-92 (right, $n = 5$). Percentages indicate frequency (\pm SEM) among CD4 T cells.

(B) PI uptake by naive ($CD45RO^-$), non- T_{FH} memory T ($CD45RO^+CXCR5^-PD-1^{low}$), T_{FH} ($CD45RO^+CXCR5^+PD-1^{high}$), or T_{FR} ($CXCR5^+ICOS^+CD25^+CD127^{low}$) cells following a 4-h incubation with either control or CAR NK-92 ($n = 8-9$). Data analyzed using Student's t test with Welch's correction.

(C) $CD4^+CXCR5^+ICOS^+T_{FH}$ uptake of Zombie viability dye following a 4-h incubation of enriched tonsillar CD4 T cells with either control or CAR NK-92 ($n = 4$). (D) $CD4^+Foxp3^+CD25^+CD127^{low}$ Treg uptake of Zombie viability dye following a 4-h incubation of enriched tonsillar CD4 T cells alone or with either control or CAR NK-92 ($n = 4-8$).

(A)–(C) represent 1 of 2 experiments, whereas (D) includes pooled data from 2 patient tonsils.

(B)–(D) Dotted lines represent PI or Zombie viability dye uptake in the absence of NK-92. Data analyzed using 1-way ANOVA.

Although no suitable *in vivo* model is available that would be characterized by secondary lymphoid tissues exhibiting follicular organization and containing both human T_{FH} and T_{FR} , the *in vivo* efficacy of PD-L1 CAR NK cells can be examined in humanized mice containing a PD-1^{high} population of CD4 T cells. Specifically, a mouse model of lupus-like disease involving human cells²⁹ was used by re-constituting human interleukin-3 (IL-3), stem cell factor (SCF), and granulocyte macrophage-colony-stimulating factor (GM-CSF) transgenic mice on an immunodeficient NOD/LtSz-SCID IL-2RG-deficient (NSGS mice) background with cord blood leukocytes for 4–5 weeks before the injection of pristane. This results in a PD-1^{high} phenotype for the majority of CD4 T cells, Ig production, and splenomegaly.²⁹ Repeated weekly infusions of 10^7 irradiated CAR-expressing NK-92 cells measurably reduced splenomegaly (Figure 4E) and CD4 T cell counts (Figure 4F) while skewing CD4 T cell phenotype toward a low expression of PD-1 relative to infusions of control NK cells (Figure 4G). In contrast, the mean (\pm SEM) number of human $CD19^+CD20^+$ B cell counts in the spleen was similar (control = $9.9 \times 10^6 \pm 9.8 \times 10^6$, CAR NK = $11.6 \times 10^6 \pm 8.9 \times 10^6$, $n = 5-6$ /group, $p = 0.77$, Student's t test), while median (\pm SD) sera human Ig (IgG) titer was slightly reduced (control = 14.3 ± 8.1 μ g/mL, CAR NK = 6.0 ± 7.1 μ g/mL,

$n = 5-6$ /group, $p = 0.34$, Mann-Whitney test). Thus, CAR NK cells selectively eliminate PD-1^{high} T cells *in vivo*.

DISCUSSION

We designed a PD-L1-based CAR that permits NK cells to selectively and efficiently target follicular T cells based upon their markedly elevated expression of PD-1 relative to other leukocytes in human blood or tonsil. Expression of this CAR construct on human NK-92 cells conferred a capacity for cytolytic degranulation in response to PD-1 presented on the surface of tissue culture plates, insect cells, Raji tumor cells, or bona fide human T_{FH} . CAR-expressing NK cells selectively eliminated T_{FH} but not B cells or naive T cells during short-term, *in vitro* co-cultures. Follicular T cell culling by CAR NK cells led to a reduction in memory B cell proliferation, differentiation, and Ig secretion *in vitro*, as well as decreased PD-1^{high} CD4 T cells and splenomegaly in a humanized mouse model of lupus-like disease. These results form the foundation of the translational development of PD-L1-based methodologies for clinical elimination of follicular T cells in certain human pathologies.




Figure 4. PD-L1 CAR NK Cells Kill T_{FH} and Suppress T-Dependent B Cell Responses

(A) Control or CAR NK-92 degranulation following a 4-h co-culture with SEB-stimulated tonsillar T_{FH} and $CD27^+$ B cells at an NK:T:B cell ratio of 5:1:2 (n = 5). (B) Percentage lysis (calcein fluorescence in supernatant) of calcein-AM-labeled, SEB-stimulated tonsillar T_{FH} and $CD27^+$ B cells after incubation with control or CAR NK-92 for 4 h at various E:T ratios. Error bars denote standard deviations.

(C) T_{FH} and $CD27^+$ B cell PI uptake following a 4-h incubation with control or CAR NK-92 (n = 4).

(D) Frequency of proliferating (CTV⁻) $CD27^+$ B cells, prevalence of $CD19^+CD27^+CD38^+$ plasmablasts, and total supernatant IgG after 7 days of SEB-stimulated co-culture with tonsillar $CD4^+$ T cells that were pre-cultured either without (“No NK”) or with control or CAR NK-92 (n = 3–8). Dotted lines and shaded areas represent measurements in the absence of NK cells. One of 2–3 similar experiments is shown.

(E–G) Human cord blood-engrafted NSGS mice injected with pristane were subsequently given weekly infusions of irradiated NK-92 or CAR NK-92 cells (n = 5–7/group, see [Method Details](#)). Resulting (E) splenomegaly, (F) splenic $CD4^+$ T cell counts, and (G) representative and mean PD-1 expression by human $CD4^+$ T cells. Pooled results of 2 independent experiments are shown.

Data analyzed via (A, C, E, and F) Student’s t test, (D) 1-way ANOVA with multiple comparisons (comparing each group to “No NK” group), and (G) Mann-Whitney test.

See also [Figure S4](#).

A limitation in the development of T_{FH} -targeting strategies is the broad expression of many T_{FH} -associated markers on other leukocytes. In the context of PD-1, we observe low but not negligible expression of this receptor on some non- T_{FH} cells, including subpopulations of NKT, CD8, and CD4 T cells. Given that these non-

T_{FH} lineages are variably implicated in the aggravation or dampening of diseases such as SLE,^{30–32} the desirability of off-target depletion of any of these cells via PD-L1 CAR-expressing cells needs to be evaluated in a disease-specific context. Peripheral blood T_{FH} exhibited the highest PD-1 expression of peripheral cells

surveyed, although roughly 6-fold less than that of their tonsillar counterparts, a finding that parallels observations made elsewhere.³³ We observed that our CAR NK cells can preferentially kill stimulated peripheral T_{FH} -like cells (Figure S4B), albeit less efficiently than tonsillar T_{FH} . Given that circulating T_{FH} are associated with SLE and can behave like GC T_{FH} ,³⁴ the elimination of circulating PD-1^{high} CD4 T cells alone will have an impact. This may be particularly important if CAR NK cells are constrained in their ability to access T_{FH} within secondary lymphoid tissues. Of note, PD-L1 CAR NK cells demonstrated more robust degranulation against PD-1^{high} cell types (e.g., PD-1^{high} S2 cells and human tonsillar T_{FH}) and exhibited a measurable cytolytic preference for T_{FH} relative to other T cell subsets. Thus, our results demonstrate that the PD-L1 CAR can confer a substantial degree of specificity for target cells based on PD-1 expression levels.

Of note, PD-1 expression in T_{FH} was exceeded only by T_{FR} , a lymphocyte population known to curtail humoral immune responses arising from GC reactions,³⁵ although recent evidence suggests a more perplexing role of T_{FR} in immunity.³⁶ Comparable non-negligible cell death (PI uptake) was observed in T_{FR} in response to both CAR NK cells and control NK cells, thus obfuscating the determination of the selectivity of CAR NK cells among follicular T cell subsets. Furthermore, given the relatively low abundance of tonsillar T_{FR} compared to T_{FH} observed (>1,600-fold less; data not shown), we predict that any ill effects of T_{FR} elimination would be largely offset by the benefits of pathogenic T_{FH} removal. This idea is supported by assays in which we enrich for CD4 T_{FH} without excluding T_{FR} , yet still see reduced B cell responses when these CD4 T cells are co-cultured with CAR NK cells. In addition, as T_{FR} differentiate from Treg cells³⁷ and we show that this population is unaltered by our CAR NK cells, the T_{FR} pool would replenish faster following CAR NK cell treatment than would be expected if they developed from T_{FH} precursors. Moreover, the suppressive effects of T_{FR} on B cell responses are mediated via durable epigenetic changes that persist in the absence of T_{FR} ,³⁸ further limiting the negative consequences of potential off-target depletion of these cells. Finally, recent findings suggest that T_{FR} regulate early but not late GC responses.³⁹ As we are proposing our CAR therapy as a potential treatment for established disease, the impact of any potential depletion of T_{FR} may therefore be less relevant to disease outcome.

Another important consideration for selective PD-L1 CAR targeting of T_{FH} is the potential for the altered expression of PD-1 on various leukocytes in the context of inflammation and disease. PD-1 expression is elevated (over baseline) on highly activated T and B lymphocytes,⁴⁰ particularly in the context of chronic inflammation or infection. These cell subsets have putative pathogenic roles in autoimmunity⁴¹ and may represent advantageous “off-target” cell populations to eradicate via CAR NK cell therapy. Changes in PD-1 expression by T_{FH} and other immune cell subsets must be subsequently evaluated in disease-specific contexts. Such analyses would increase confidence in the capacity of PD-L1 CAR-based strategies to selectively eliminate T_{FH} or a combination of T_{FH} and other pathogenic cell types in a particular human disease state.

The choice of PD-L1 as a targeting molecule may result in additional off-target effects due to low-affinity interactions be-

tween PD-L1 and CD80/B7-1.²⁴ We observed that, when compared to PD-1, much higher concentrations of CD80 are necessary to trigger the degranulation of PD-L1 CAR-expressing NK cells (data not shown). Moreover, CD80 expression levels on select subpopulations of leukocytes, including B cells and other antigen-presenting cells,⁴² are relatively low. Although unlikely to occur, off-target PD-L1 CAR NK cell killing of CD80-expressing cells *in vivo* could help to lessen disease by reducing CD80-mediated co-stimulation of immune responses. In fact, targeting CD80 ameliorates lupus-like disease in mice.⁴³ Nevertheless, T_{FH} are also characterized by the elevated surface expression of other markers, such as ICOS,¹ which could be similarly targeted in next-generation CAR constructs. Alternatively, PD-1 is also recognized by PD-L2, a ligand with higher affinity for PD-1 but no reported off-target binding to CD80.²⁴

Numerous other enhancements could be adopted from the rapidly evolving CAR field to increase the safety and functional capacity of our T_{FH} -targeted CAR NK cells. For example, the “second-generation” CAR used in our study contains signaling domains of CD28 and CD3 ζ that are optimized for CAR T cell function. Recent studies reveal that the inclusion of “third-generation” components to specifically enhance persistence (e.g., IL-15) or co-stimulation (e.g., NKG2D) of NK cells can elevate CAR efficacy.^{17,18} Although the potential toxicity of selectively eliminating T_{FH} remains unexplored, the preservation of naive and memory CD4 T cells as well as B cells and other types of immune cells suggests that the state of immunodeficiency induced by the PDL1 CAR NK cells will be far less severe than other immunotherapeutic strategies applied to autoimmune disease (e.g., rituximab). Moreover, the fact that PDL1 CAR NK spare the Treg compartment should prevent major immunopathological reactions with this therapy. CAR NK cells in general have an impressive safety profile despite their robust ability to eradicate malignant lymphocyte populations. Nevertheless, efforts are being made to introduce “suicide switches” into CAR NK cells^{17,19}—a feature that may be critical to the safety of our PD-L1 CAR NK cells for safe clinical use.

In addition, CAR-mediated elimination of T_{FH} likely will require efficient localization of CAR-expressing NK or T cells in the follicular regions of secondary and even tertiary lymphoid structures (TLSs). Of note, T_{FH} are found in the TLSs of patients with SLE⁴⁴ and other autoimmune diseases,^{45,46} in which they exhibit a high expression of PD-1 and may contribute to pathogenesis. Engineered expression of CXCR5 on PD-L1 CAR NK cells is likely to improve trafficking to the sites of T_{FH} residence throughout the body. This would mirror observed migration patterns of CXCR5⁺ T or NK cells naturally present^{47,48} or artificially engineered⁴⁹ during chronic virus infection, and may provoke beneficial consequences for patients with T_{FH} -driven diseases.

The use of the extracellular domain of PD-L1 in the targeting region of our CAR to selectively eliminate PD-1^{high} T_{FH} represents a repurposing of CAR technology for use in autoimmunity and other human diseases. The initial success of our strategy illuminates a promising avenue for the development of therapeutics for targeting T_{FH} or other pathogenic leukocytes that lack specific target molecules for antibody-mediated targeting. PD-L1-based targeting of T_{FH} could be incorporated into CAR T cells, bi-specific killer engager (BiKE), or other

immunotherapeutic modalities.¹⁷ Although the effects herein are achieved via a human NK cell line, we envision a therapeutic approach that uses (autologous) primary or induced pluripotent stem cell-derived NK cells that are engineered to express our PD-L1 CAR via mRNA transfection, transposon technology, or viral delivery. Such innovative strategies represent a readily amenable platform for the treatment of deadly and intractable diseases such as SLE.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
 - Cell lines
 - Human subjects and primary cell cultures
 - Microbes
 - Animals
- **METHOD DETAILS**
 - Cell counting & microscopy
 - Tissue processing for human tonsil and peripheral blood mononuclear cells
 - Flow cytometry & cell sorting
 - PD-L1 CAR and PD-1-containing vectors
 - Lentivirus generation and lentiviral transduction of NK-92 cells
 - Generation of PD-1-expressing target cell lines
 - qPCR
 - Plate-bound activation assays
 - NK-92 co-culture activation and cytotoxicity assays
 - Evaluating CAR NK-92 function in humanized mice
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
- **DATA AND CODE AVAILABILITY**

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.xcrm.2020.100003>.

ACKNOWLEDGMENTS

The authors acknowledge D. Krishnamurthy, D. Ohayon, and M. Khodoun for technical assistance; H. Seelamneni for lab managerial support; E. Fjellman and C. Forney for helping to obtain and process tissues; D. Miller and A. Sauder for cloning support; L. Ding for statistical expertise; and E. Long, S. Borrow, D. Peppas, and I. Pedroza-Pacheco for expert advice. Funding was provided by the Dr. Ralph and Marian Falk Medical Research Trust Catalyst Awards Program and NIH grants DA038017, T32GM063483, T32AI118697, AI148080, and AR073228. Support was also provided by the Cincinnati Children's Viral Vector Core, the Flow Cytometry Core, and the Functional Genomics Core (NIH grants AR070549 and S10OD023410), as well as the Cincinnati Children's Research Foundation and Academic Research Centers award.

AUTHOR CONTRIBUTIONS

Conceptualization, S.D.R., S.N.W., and H.I.B.; Methodology, S.D.R., S.N.W., I.E.G., A.A., A.T.D.-L., L.C.K., M.V.K., and D.F.S.; Investigation, S.D.R., S.A.C., K.M.R., J.A.T., A.A., and A.T.D.-L.; Formal Analysis, S.D.R., S.N.W.,

M.V.K., and A.A.; Resources, L.C.K., D.F.S., I.E.G., and A.T.D.-L.; Writing – Original Draft, S.D.R. and S.N.W.; Writing – Review & Editing, S.D.R., S.N.W., S.A.C., K.M.R., A.A., I.E.G., A.T.D.-L., J.A.T., L.C.K., D.F.S., M.V.K., and H.I.B.; Visualization, S.D.R., S.N.W., and S.A.C.; Funding Acquisition, S.N.W., H.I.B., and S.D.R.

DECLARATION OF INTERESTS

S.D.R., H.I.B., and S.N.W. are listed as inventors on a pending patent covering the technology described in this article. S.A.C. is an employee of and shareholder in Poseida Therapeutics, which is commercializing cellular therapies. The remaining authors declare no competing interests.

Received: February 1, 2019

Revised: January 30, 2020

Accepted: March 2, 2020

Published: March 25, 2020; corrected online September 10, 2020

REFERENCES

1. Crotty, S. (2011). Follicular helper CD4 T cells (TFH). *Annu. Rev. Immunol.* **29**, 621–663.
2. Vinuesa, C.G., Linterman, M.A., Yu, D., and MacLennan, I.C. (2016). Follicular Helper T Cells. *Annu. Rev. Immunol.* **34**, 335–368.
3. Victora, G.D., and Nussenzweig, M.C. (2012). Germinal centers. *Annu. Rev. Immunol.* **30**, 429–457.
4. Tangye, S.G., Ma, C.S., Brink, R., and Deenick, E.K. (2013). The good, the bad and the ugly - TFH cells in human health and disease. *Nat. Rev. Immunol.* **13**, 412–426.
5. Craft, J.E. (2012). Follicular helper T cells in immunity and systemic autoimmunity. *Nat. Rev. Rheumatol.* **8**, 337–347.
6. Vinuesa, C.G., Sanz, I., and Cook, M.C. (2009). Dysregulation of germinal centres in autoimmune disease. *Nat. Rev. Immunol.* **9**, 845–857.
7. Blanco, P., Ueno, H., and Schmitt, N. (2016). T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. *Eur. J. Immunol.* **46**, 281–290.
8. Choi, J.Y., Ho, J.H., Pasoto, S.G., Bunin, V., Kim, S.T., Carrasco, S., Borba, E.F., Gonçalves, C.R., Costa, P.R., Kallas, E.G., et al. (2015). Circulating follicular helper-like T cells in systemic lupus erythematosus: association with disease activity. *Arthritis Rheumatol.* **67**, 988–999.
9. Vinuesa, C.G., Cook, M.C., Angelucci, C., Athanasopoulos, V., Rui, L., Hill, K.M., Yu, D., Domaschenz, H., Whittle, B., Lambe, T., et al. (2005). A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. *Nature* **435**, 452–458.
10. Linterman, M.A., Rigby, R.J., Wong, R.K., Yu, D., Brink, R., Cannons, J.L., Schwartzberg, P.L., Cook, M.C., Walters, G.D., and Vinuesa, C.G. (2009). Follicular helper T cells are required for systemic autoimmunity. *J. Exp. Med.* **206**, 561–576.
11. Kobayashi, T., Iijima, K., Dent, A.L., and Kita, H. (2017). Follicular helper T cells mediate IgE antibody response to airborne allergens. *J. Allergy Clin. Immunol.* **139**, 300–313.e7.
12. Ahearn, M.J., Allchin, R.L., Fox, C.P., and Wagner, S.D. (2014). Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. *Br. J. Haematol.* **166**, 326–335.
13. Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., and June, C.H. (2014). Chimeric antigen receptor therapy for cancer. *Annu. Rev. Med.* **65**, 333–347.
14. Guedan, S., Calderon, H., Posey, A.D., Jr., and Maus, M.V. (2018). Engineering and Design of Chimeric Antigen Receptors. *Mol. Ther. Methods Clin. Dev.* **12**, 145–156.
15. Anwer, F., Shaikat, A.A., Zahid, U., Husnain, M., McBride, A., Persky, D., Lim, M., Hasan, N., and Riaz, I.B. (2017). Donor origin CAR T cells: graft

versus malignancy effect without GVHD, a systematic review. *Immunotherapy* 9, 123–130.

16. Neelapu, S.S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F.L., Komanduri, K.V., Lin, Y., Jain, N., Daver, N., et al. (2018). Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. *Nat. Rev. Clin. Oncol.* 15, 47–62.
17. Daher, M., and Rezvani, K. (2018). Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. *Curr. Opin. Immunol.* 51, 146–153.
18. Li, Y., Hermanson, D.L., Moriarity, B.S., and Kaufman, D.S. (2018). Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. *Cell Stem Cell* 23, 181–192.e5.
19. Liu, E., Marin, D., Banerjee, P., Macapinlac, H.A., Thompson, P., Basar, R., Nassif Kerbaudy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020). Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. *N. Engl. J. Med.* 382, 545–553.
20. Tang, X., Yang, L., Li, Z., Nalin, A.P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., Shen, W., et al. (2018). First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. *Am. J. Cancer Res.* 8, 1083–1089.
21. Siegler, E.L., Zhu, Y., Wang, P., and Yang, L. (2018). Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy. *Cell Stem Cell* 23, 160–161.
22. Caruso, H.G., Hurton, L.V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015). Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. *Cancer Res.* 75, 3505–3518.
23. Chmielewski, M., Hombach, A., Heuser, C., Adams, G.P., and Abken, H. (2004). T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. *J. Immunol.* 173, 7647–7653.
24. Butte, M.J., Peña-Cruz, V., Kim, M.J., Freeman, G.J., and Sharpe, A.H. (2008). Interaction of human PD-L1 and B7-1. *Mol. Immunol.* 45, 3567–3572.
25. Cheng, X., Veverka, V., Radhakrishnan, A., Waters, L.C., Muskett, F.W., Morgan, S.H., Huo, J., Yu, C., Evans, E.J., Leslie, A.J., et al. (2013). Structure and interactions of the human programmed cell death 1 receptor. *J. Biol. Chem.* 288, 11771–11785.
26. Klingemann, H., Boissel, L., and Tneguzzo, F. (2016). Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells. *Front. Immunol.* 7, 91.
27. March, M.E., Gross, C.C., and Long, E.O. (2010). Use of transfected *Drosophila* S2 cells to study NK cell activation. *Methods Mol. Biol.* 672, 67–88.
28. Herman, A., Labrecque, N., Thibodeau, J., Marrack, P., Kappler, J.W., and Sekaly, R.P. (1991). Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR. *Proc. Natl. Acad. Sci. USA* 88, 9954–9958.
29. Gunawan, M., Her, Z., Liu, M., Tan, S.Y., Chan, X.Y., Tan, W.W.S., Dharmaraja, S., Fan, Y., Ong, C.B., Loh, E., et al. (2017). A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice. *Sci. Rep.* 7, 16642.
30. Tsokos, G.C., Lo, M.S., Costa Reis, P., and Sullivan, K.E. (2016). New insights into the immunopathogenesis of systemic lupus erythematosus. *Nat. Rev. Rheumatol.* 12, 716–730.
31. Wu, L., and Van Kaer, L. (2011). Natural killer T cells in health and disease. *Front. Biosci. (Schol. Ed.)* 3, 236–251.
32. Blanco, P., Pitard, V., Viallard, J.F., Taupin, J.L., Pellegrin, J.L., and Moreau, J.F. (2005). Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. *Arthritis Rheum.* 52, 201–211.
33. Locci, M., Havenar-Daughton, C., Landais, E., Wu, J., Kroenke, M.A., Arlehamn, C.L., Su, L.F., Cubas, R., Davis, M.M., Sette, A., et al.; International AIDS Vaccine Initiative Protocol C Principal Investigators (2013). Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity* 39, 758–769.
34. Zhang, X., Lindwall, E., Gauthier, C., Lyman, J., Spencer, N., Alarakhia, A., Fraser, A., Ing, S., Chen, M., Webb-Detiege, T., et al. (2015). Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. *Lupus* 24, 909–917.
35. Linterman, M.A., Pierson, W., Lee, S.K., Kallies, A., Kawamoto, S., Rayner, T.F., Srivastava, M., Divekar, D.P., Beaton, L., Hogan, J.J., et al. (2011). Foxp3+ follicular regulatory T cells control the germinal center response. *Nat. Med.* 17, 975–982.
36. Xie, M.M., Fang, S., Chen, Q., Liu, H., Wan, J., and Dent, A.L. (2019). Follicular regulatory T cells inhibit the development of granzyme B-expressing follicular helper T cells. *JCI Insight* 4, 128076.
37. Essig, K., Hu, D., Guimaraes, J.C., Alterauge, D., Edelmann, S., Raj, T., Kranich, J., Behrens, G., Heiseke, A., Floess, S., et al. (2017). Roquin Suppresses the PI3K-mTOR Signaling Pathway to Inhibit T Helper Cell Differentiation and Conversion of Treg to Tfr Cells. *Immunity* 47, 1067–1082.e12.
38. Sage, P.T., Ron-Harel, N., Juneja, V.R., Sen, D.R., Maleri, S., Sungnak, W., Kuchroo, V.K., Haining, W.N., Chevrier, N., Haigis, M., and Sharpe, A.H. (2016). Suppression by T_{FR} cells leads to durable and selective inhibition of B cell effector function. *Nat. Immunol.* 17, 1436–1446.
39. Clement, R.L., Daccache, J., Mohammed, M.T., Diallo, A., Blazar, B.R., Kuchroo, V.K., Lovitch, S.B., Sharpe, A.H., and Sage, P.T. (2019). Follicular regulatory T cells control humoral and allergic immunity by restraining early B cell responses. *Nat. Immunol.* 20, 1360–1371.
40. Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D.M., Okumura, K., et al. (2002). Expression of programmed death 1 ligands by murine T cells and APC. *J. Immunol.* 169, 5538–5545.
41. Curran, C.S., Gupta, S., Sanz, I., and Sharon, E. (2019). PD-1 immunobiology in systemic lupus erythematosus. *J. Autoimmun.* 97, 1–9.
42. Liu, S.M., Xavier, R., Good, K.L., Chtanova, T., Newton, R., Sisavanh, M., Zimmer, S., Deng, C., Silva, D.G., Frost, M.J., et al. (2006). Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes. *J. Allergy Clin. Immunol.* 118, 496–503.
43. Shi, Q., Gao, Z.Y., Xie, F., Wang, L.F., Gu, Y.P., Yang, T.J., Huang, L., Qian, Q.H., and Qiu, Y.H. (2011). A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease. *Int. J. Immunopathol. Pharmacol.* 24, 583–593.
44. Liarski, V.M., Kaverina, N., Chang, A., Brandt, D., Yanez, D., Talasnik, L., Carlesso, G., Herbst, R., Utset, T.O., Labno, C., et al. (2014). Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. *Sci. Transl. Med.* 6, 230ra46.
45. Rao, D.A., Gurish, M.F., Marshall, J.L., Slowikowski, K., Fonseka, C.Y., Liu, Y., Donlin, L.T., Henderson, L.A., Wei, K., Mizoguchi, F., et al. (2017). Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. *Nature* 542, 110–114.
46. Taylor, D.K., Mittereder, N., Kuta, E., Delaney, T., Burwell, T., Dacosta, K., Zhao, W., Cheng, L.I., Brown, C., Boutrin, A., et al. (2018). T follicular helper-like cells contribute to skin fibrosis. *Sci. Transl. Med.* 10, eaaf5307.
47. He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016). Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection. *Nature* 537, 412–428.

48. Huot, N., Jacquelin, B., Garcia-Tellez, T., Rascle, P., Ploquin, M.J., Madec, Y., Reeves, R.K., Derreudre-Bosquet, N., and Müller-Trutwin, M. (2017). Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys. *Nat. Med.* 23, 1277–1286.
49. Ayala, V.I., Deleage, C., Trivett, M.T., Jain, S., Coren, L.V., Breed, M.W., Kramer, J.A., Thomas, J.A., Estes, J.D., Lifson, J.D., and Ott, D.E. (2017). CXCR5-Dependent Entry of CD8 T Cells into Rhesus Macaque B-Cell Follicles Achieved through T-Cell Engineering. *J. Virol.* 91, e02507-16.
50. Wunderlich, M., Chou, F.S., Link, K.A., Mizukawa, B., Perry, R.L., Carroll, M., and Mulloy, J.C. (2010). AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. *Leukemia* 24, 1785–1788.
51. Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J.B., Victor, A., Meisen, W.H., Kim, S.H., Grandi, P., et al. (2015). CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. *Sci. Rep.* 5, 11483.
52. Somanchi, S.S., Senyukov, V.V., Denman, C.J., and Lee, D.A. (2011). Expansion, purification, and functional assessment of human peripheral blood NK cells. *J. Vis. Exp.* (48), 2540.
53. Wunderlich, M., Mizukawa, B., Chou, F.S., Sexton, C., Shrestha, M., Sauntharajah, Y., and Mulloy, J.C. (2013). AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. *Blood* 121, e90–e97.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Anti-human/mouse BCL6 PerCP-Cy5.5	Biolegend	RRID:AB_2566191
Anti-human CD279 PE	Biolegend	RRID:AB_940483
Anti-human CD3 BV421	Biolegend	RRID:AB_2565849
Anti-human CD4 BV510	Biolegend	RRID:AB_2561377
Anti-human CD8 APC	Biolegend	RRID:AB_2075390
Anti-human CD185 BV711	Biolegend	RRID:AB_2629525
Anti-human CD278 BV650	Biolegend	RRID:AB_2749928
Anti-human CD45RA APC-Cy7	Biolegend	RRID:AB_10708419
Anti-human CD45RO PE-Cy7	Biolegend	RRID:AB_11203903
Anti-human FOXP3 AF488	Biolegend	RRID:AB_430882
Anti-human CD25 BV785	Biolegend	RRID:AB_11219197
Anti-human CD45 AF488	Biolegend	RRID:AB_493033
Anti-human CD20 BV650	Biolegend	RRID:AB_11218609
Anti-human CD27 BV785	Biolegend	RRID:AB_2562674
Anti-human CD38 APC-Cy7	Biolegend	RRID:AB_2562576
Anti-human CD138 BV421	Biolegend	RRID:AB_2562659
Anti-human IgG Fc APC	Biolegend	RRID:AB_11150590
Anti-human IgM PE-Cy7	Biolegend	RRID:AB_2566484
Anti-human IgD BV510	Biolegend	RRID:AB_2561386
Anti-human CD21 PerCP-Cy5.5	Biolegend	RRID:AB_2561543
Anti-human CD45 BV785	Biolegend	RRID:AB_2715888
Anti-human CD3 BV605	Biolegend	RRID:AB_11126166
Anti-human CD19 BV711	Biolegend	RRID:AB_2562062
Anti-human CD56 AF488	Biolegend	RRID:AB_2564093
Anti-human CD11b PerCP-Cy5.5	Biolegend	RRID:AB_10900072
Anti-human CD68 APC-Cy7	Biolegend	RRID:AB_2571964
Anti-human CD14 PE-Cy7	Biolegend	RRID:AB_830690
Anti-human CD1c APC	Biolegend	RRID:AB_10718511
Anti-human HLA-DR BV421	Biolegend	RRID:AB_10897449
Anti-human CD16 BV510	Biolegend	RRID:AB_2562085
Anti-human CD56 BV421	Biolegend	RRID:AB_10900228
Anti-human CD27 AF488	Biolegend	RRID:AB_2565545
Anti-human CD107a AF647	Biolegend	RRID:AB_1227506
Anti-human CD107a PE-Cy7	Biolegend	RRID:AB_11147955
Anti-human CD3 PE	Biolegend	RRID:AB_314044
Anti-human CD19 APC	Biolegend	RRID:AB_314242
Anti-human CD4 BV711	Biolegend	RRID:AB_11219404
Anti-human CXCR5 BV785	Biolegend	RRID:AB_2629527
Anti-human CXCR5 AF488	Biolegend	RRID:AB_2561894
Anti-human CD279 BB700	BD Biosciences	RRID:AB_2744348
Anti-human CD19 BV421	Biolegend	RRID:AB_10897802
Anti-human CD3 PE-Cy7	Biolegend	RRID:AB_439781
Anti-human CXCR5 BB700	BD Biosciences	RRID:AB_2739739

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Anti-human CD127 PE-Cy7	Biolegend	RRID:AB_10899414
Anti-human PD-1 APC	Biolegend	RRID:AB_940475
Anti-human FOXP3 eF450	Thermo Fisher	RRID:AB_1834364
Anti-human CD274 PE	Biolegend	RRID:AB_940368
Anti-human CD274 APC	Biolegend	RRID:AB_2749927
Anti-human PD-L1	R&D Systems	RRID:AB_2073445
Normal goat IgG control Antibody	R&D Systems	RRID:AB_354267
Anti-human CD3	Bio X Cell	RRID:AB_1107632
Bacterial and Virus Strains		
DH5 α <i>E. coli</i>	NEB	Cat# C2987H
XL10 Gold <i>E. coli</i>	Agilent	Cat# 200315
Stbl3 <i>E. coli</i>	Invitrogen	Cat# C737303
StellarComp <i>E. coli</i>	Clontech	Cat# 636763
VSV-G pseudotyped lentiviral vector	Viral Vector Core, Cincinnati Children's Hospital Medical Center	https://www.cincinnatichildrens.org/research/cores/translational-core-laboratory/viral-vector-core/team
Biological Samples		
Human tonsillar tissue	Division of Pediatric Otolaryngology-Head and Neck Surgery (Cincinnati Children's Hospital Medical Center)	https://www.cincinnatichildrens.org/research/divisions/o/otolaryngology
Human cord blood	Cell Manipulations Laboratory & Cell Processing Core (Cincinnati Children's Hospital Medical Center)	https://www.cincinnatichildrens.org/research/cores/translational-core-laboratory/cell-manipulations-laboratory https://www.cincinnatichildrens.org/research/cores/translational-core-laboratory/cell-processing-core
Leukocyte reduction filters (source of human PBMC)	University of Cincinnati Hoxworth Blood Center	https://hoxworth.org/
Chemicals, Peptides, and Recombinant Proteins		
Collagenase D	Roche	Cat# 11088793001
Recombinant Human IL-2	Peptotech	Cat# 200-02
DNase 1	Millipore Sigma	Cat# 11284932001
Ficoll-Paque PLUS	GE Healthcare	Cat# 17144002
BD Cytotfix Fixation Buffer	BD Biosciences	Cat# 554655
BD Cytotfix/Cytoperm Fixation and Permeabilization Solution	BD Biosciences	Cat# 554714
Perm/Wash Buffer	BD Biosciences	Cat# 554723
Ampicillin	GoldBio	Cat# A-301-25
Kanamycin	GoldBio	Cat# K-120
T4 DNA Ligase	New England BioLabs	Cat# M0202S
Human Fibronectin	Invitrogen	Cat# PHE0023
Protamine Sulfate	Fisher	Cat# ICN10275205
Blasticidin	Fisher	Cat# K515001
Puromycin	GIBCO	Cat# A1113803
rhPD-1-Fc	R&D Systems	Cat# 1086-PD-050
IgG1-Fc	R&D Systems	Cat# 110-HG-100
PMA	Sigma-Aldrich	Cat# P8139
Ionomycin	Sigma-Aldrich	Cat# I9657-1MG

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Zombie UV Dye	Biolegend	Cat# 423107
SEB	EMD Millipore	Cat# 324798; CAS# 11100-45-1
Calcein AM Solution	Fisher	Cat# C34852
Propidium Iodide	Biolegend	Cat# 421301
Chromium-51	Perkin Elmer	Cat# NEZ030S002MC
CellTrace Violet	Invitrogen	Cat# C34557
Pristane	Sigma-Aldrich	Cat# P9622-10X1ML
Bulsulfan	Sigma-Aldrich	Cat# B2635-25G
UltraComp eBeads Compensation Beads	ThermoFisher	Cat# 01-2222-42
Critical Commercial Assays		
DES Blasticidin Support Kit	Invitrogen	Cat# K515001
DES-Inducible Kit with pCoBlast	Invitrogen	Cat# K512001
GeneJET Gel Extraction kit	ThermoFisher	Cat# K0692
QIAprep Mini, Midi, Maxi Kits	QIAGEN	Cat# 27106, 12943, 12362
Rneasy Mini Kit	QIAGEN	Cat# 74104
iScript cDNA Synthesis Kit	Bio-Rad	Cat# 170-8891
PrimeTime Gene Expression Master Mix	IDT Technologies	Cat# 1055770
TaqMan Gene Expression Assay	ThermoFisher	Cat# 4331182
Easy Sep Human CD4+ T cell Isolation kit	StemCell Technologies	Cat# 17952
Easy Sep Human B cell Isolation kit	StemCell Technologies	Cat# 17954
Human IgG total ELISA Ready-SET-Go! Kit	eBioscience	Cat# 50-112-8669
Experimental Models: Cell Lines		
Drosophila S2 cell line	ThermoFisher	Cat# R69007
HEK293T cell line	ATCC	RRID:CVCL_0063
NK-92 cell line	ATCC	RRID:CVCL_2142
Raji cell line	ATCC	RRID:CVCL_0511
Experimental Models: Organisms/Strains		
Mouse: NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ	Wunderlich et al., 2010 ⁵⁰	RRID:IMSR_JAX:013062
Oligonucleotides		
Primer/probe sets for CAR expression qPCR	This paper	Table S1
Sequencing primers PD-L1 CAR plasmid	This paper	Table S1
Sequencing primers PD-1 pAc/V5-His plasmid	This paper	Table S1
Sequencing primers PD-1 PB513 plasmid	This paper	Table S1
Recombinant DNA		
Human PDL1-CD28-CD3ζ chimeric antigen receptor	This paper	n/a
Human PD-1 protein sequence	Uniprot (a.a. 1-288)	n/a
pLVX-IRES-ZsGreen1 Vector	Clontech	Cat# 632187
pUC57-Kan plasmid vector	GeneWiz	n/a
pAc5.1/V5-His A Plasmid Vector	Invitrogen	Cat# V411020
PiggyBac Transposon, Cloning and Expression Vector	System Biosciences	Cat# PB513B-1
Super PiggyBac Transposase Expression Vector	System Biosciences	Cat# PB210PA-1
pcDNA3.1/His/lacZ	Invitrogen	Cat# V38520
pAc5.1/V5-His A	Invitrogen	Cat# V411020

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Software and Algorithms		
Sony SH800S Cell Sorter acquisition software	Sony Biotechnologies	https://www.sonybiotechnology.com/us/instruments/sh800s-cell-sorter/software/
Snapgene	GSL Biotech	https://www.snapgene.com/
Molecular Biology tool	Benchling	https://www.benchling.com/
"Codon Optimization Tool"	IDT Technologies	https://www.idtdna.com/pages/tools
NIS-Elements Imaging Software	Nikon	https://www.microscope.healthcare.nikon.com/products/software
FACSDiva	BD Biosciences	https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-software/flow-cytometry-acquisition/facsdiva-software
FlowJo v.10 Software	TreeStar Inc.	https://www.flowjo.com/
Prism 7	GraphPad	https://www.graphpad.com/scientific-software/prism/
Nonlinear Regression (curve fit)	GraphPad Prism	https://www.graphpad.com/guides/prism/7/curve-fitting/index.htm?REG_DR_stim_variable_2.htm

LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen Waggoner (Stephen.Waggoner@cchmc.org). The chimeric antigen receptor (CAR) construct and other reagents generated in this study will be made available from the Lead Contact for academic/non-commercial research purposes on request under a Material Transfer Agreement. Commercial use of the CAR would be subject to a licensing agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell lines

The NK-92 (ATCC CRL-2407) cell line, of human male origin, was obtained directly from ATCC and cultured at 37°C in Minimum Essential Medium Alpha without ribonucleosides or deoxyribonucleosides and with 2 mM L-glutamine and 1.5 g/L sodium bicarbonate (GIBCO), further supplemented with 0.2 mM inositol; 0.1 mM 2-mercaptoethanol; 0.02 mM folic acid; 100 U/ml recombinant IL-2 (PeproTech), 12.5% heat-inactivated (HI) horse serum and 12.5% HI fetal bovine serum (henceforth referred to as "NK-92 media"). Half of the media was refreshed every 2-3 days with seeding at 2-3x10⁵ cells/mL in fresh, non-tissue culture-treated flasks (Corning) to prevent adherence and better facilitate natural clumping of cells. The Raji cell line (ATCC CCL-86), of human male origin, was obtained directly from ATCC and cultured at 37°C in RPMI-1640 (HyClone) supplemented with 10% HI-FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin (henceforth referred to as "Raji media"). Cultures were established by re-suspending cells at 4x10⁵ cells/mL in tissue culture-treated flasks (Corning) and refreshing media every 2-3 days, maintaining a maximum density of 3x10⁶ cells/mL. S2 cells, of *Drosophila melanogaster* origin, were obtained from ThermoFisher and cultured in Schneider's *Drosophila* Media (ThermoFisher) supplemented with 10% HI-FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin (henceforth referred to as "S2 media") according to a published protocol²⁷. Specifically, cells were grown in tissue culture-treated flasks (Corning) at room temperature, protected from light, maintained at a concentration of 1-2.5x10⁶/mL, and passaged every 2-3 days at a 1:3 ratio of cell suspension to fresh media. When necessary for selection, blasticidin or puromycin were added to culture medium at a concentration of 25 µg/mL and 2 µg/mL, respectively. Cell line authentication was not performed. Heat inactivation of FBS was accomplished via incubation in a 56°C water bath for 30 minutes.

Human subjects and primary cell cultures

Peripheral blood mononuclear cells (PBMC) were collected from fresh and fully de-identified leukocyte reduction filters obtained from five healthy adult blood donors at the University of Cincinnati Hoxworth Blood Center with Institutional Review Board (IRB) approval at Cincinnati Children's Hospital Medical Center. One male and four female children, two to seven years of age requiring tonsillectomy were recruited to a prospective study at a tertiary academic care center through the Division of Pediatric Otolaryngology-Head and Neck Surgery at Cincinnati Children's Hospital Medical Center with prior IRB approval. Criteria for enrollment in the study included a history of sleep-disordered breathing or recurrent or chronic tonsillitis requiring removal of the tonsillar tissue. Consent

was obtained from parents in the perioperative suite on the day of the procedure. Subjects were excluded from the study if the tonsillar tissue was acutely infected or if anatomic abnormalities were present requiring a more detailed pathologic evaluation. After recruitment, patients underwent tonsillectomy as part of the standard of practice. Upon removal, approximately half of each of the bilateral tonsils were transected and placed in RPMI-1640 media supplemented with 10% human AB serum (Sigma). Samples were labeled with a de-identified barcode and transferred to the research team for further processing. The remaining tonsillar tissue was sent to pathology for gross evaluation as part of the routine clinical care. Entirely de-identified human cord blood samples from three healthy neonates (collected as part of the standard of care) were obtained from the Cell Manipulations Laboratory and Cell Processing Core at Cincinnati Children's Hospital Medical Center with prior IRB approval. All cultures involving primary human tonsillar lymphocytes or human PBMC were performed in RPMI-1640 (HyClone) supplemented with 10% HI-FBS, 100 U/mL penicillin, 100 μ g/mL streptomycin, 1 mM sodium pyruvate, 10 mM HEPES buffer, 1X MEM non-essential amino acids, and 0.1 mM 2-beta-mercaptoethanol (henceforth referred to as "cRPMI").

Microbes

E. coli strains DH5 α , XL10-Gold, Stbl3, and StellarComp were grown in standard lysogeny broth (LB) or on LB agar plates containing the appropriate selective antibiotic (50 μ g/mL ampicillin or 100 μ g/mL kanamycin) in a 37°C incubator.

Animals

Eight-week-old male and female human IL-3/SCF/GM-CSF transgenic mice on an immune-deficient NOD/LtSz-SCID IL-2RG^{-/-} background (NSGS mice; NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl} Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ), first described elsewhere⁵⁰, were bred in-house and kept on doxycycline chow at all times. Littermates of the same sex were randomly assigned to treatment groups. Mice were maintained under specific pathogen-free conditions in accordance with guidelines from the Association for Assessment and Accreditation of Laboratory Animal Care International. Experiments were performed in accordance with ethical guidelines approved by the Institutional Animal Use and Care Committee of Cincinnati Children's Hospital Medical Center.

METHOD DETAILS

Cell counting & microscopy

All cell enumerations were obtained with a hemocytometer using Trypan Blue exclusion. Fluorescent cell images were taken using a Nikon Eclipse Ti microscope, equipped with Zyla sCMOS camera (Andor) and 488nm filter cube, and processed using NIS-Elements Imaging software (Nikon).

Tissue processing for human tonsil and peripheral blood mononuclear cells

Human tonsil tissue was processed by mincing with scissors followed by transfer of up to 4g of tissue to a gentleMACS C tube (Miltenyi Biotec) containing 8 mL of phosphate-buffered saline (PBS) with 0.5 mg/mL collagenase D and 3000 U/mL DNaseI, then dissociated on a GentleMACS Octo Dissociator (Miltenyi Biotec) using "program C." Tissue homogenates were incubated in a 37°C water bath for 15 minutes, then dissociated again using "program C" and transferred through a 100 μ m cell strainer into cRPMI. This cell suspension was then layered over Ficoll-Paque PLUS (GE Healthcare) and subjected to density-gradient separation via centrifugation at 1200 g for 20 minutes with the brake turned off to isolate tonsillar mononuclear cells at the interphase layer. Human peripheral leukocytes were dislodged from blood-donor leukocyte reduction filters via thorough washing with pre-warmed PBS, then subjected to density-gradient centrifugation over Ficoll-Paque PLUS as described above to obtain PBMC at the interphase layer. All PBMC and tonsil mononuclear cells were cryopreserved in FBS containing 10% dimethyl sulfoxide and frozen at -1°C/min using CoolCell freezing containers (BioCision) to -80°C, then stored long-term in vapor phase liquid nitrogen. Cryopreserved cells were rapidly thawed in a 37°C water bath, transferred into warm cRPMI, and washed twice with cRPMI before subsequent use.

Flow cytometry & cell sorting

Fluorescently conjugated antibodies used were obtained from either Biolegend, ebioscience (ThermoFisher), or BD Biosciences. Antibodies were directed against either human BCL-6, CD279 (PD-1), CD3, CD4, CD8, CD185 (CXCR5), CD278 (ICOS), CD45RA, CD45RO, FOXP3, CD25, CD45, CD19, CD20, CD27, CD38, CD138, IgG-Fc, IgM, IgD, CD21, CD56, CD11b, CD68, CD14, CD1c, HLA-DR, CD16, CD107a (LAMP-1), CD127, or CD274 (PD-L1). Antibodies were conjugated to one of the following fluorescent proteins: eFluor450, BV421, BV510, BV605, BV650, BV711, BV785, PE, APC, APC-Cy7, BB700, PerCP-Cy5.5, Alexa Fluor 488, or Alexa Fluor 647. For surface staining, cells were resuspended at a concentration of 1-2 \times 10⁶/mL in 50-100 μ L of cold Hank's Buffered Salt Solution (HBSS) containing 5% HI-FBS, 100 U/mL penicillin, and 100 μ g/mL streptomycin ("FACS buffer"). Fluorescently conjugated antibodies were each added at the manufacturer's recommended concentration. Cells were incubated in a 4°C fridge in the dark for 20 minutes, then washed twice with FACS buffer. Washed cells were either analyzed fresh (same day), fixed using 100 μ L BD Cytotfix for 20 minutes at 4°C, or stained for intracellular markers. Intracellular staining was performed by fixation/permeabilization of surface-stained cells in 100 μ L Cytotfix/Cytoperm (BD Biosciences) for 20 minutes at 4°C, followed by staining as above in 100 μ L of 1x Perm/Wash buffer (BD Biosciences) containing fluorescently-conjugated antibodies, each at the manufacturer's recommended concentration, for 20 minutes at 4°C. All fixed cells were washed twice with FACS buffer to remove fixative and kept in 4°C fridge in

FACS buffer until analysis (1-3 days later). Acquisition of stained cells was performed using a Fortessa or LSRII cytometer (BD Biosciences) with FACSDiva software (BD Biosciences). Flow cytometric cell sorting was performed using an SH800S cell sorter (Sony) with the accompanying Sony acquisition software. All flow cytometric analysis was performed using FlowJo v.10 software. Compensation was performed using single-color-stained cells and/or UltraComp eBeads (ThermoFisher), and all electronic gating was performed downstream of an FSC-H x FSC-A “singlet” gate.

PD-L1 CAR and PD-1-containing vectors

In general, plasmid amplifications were performed by transformation and expansion of the competent *E. coli* strains DH5 α or XL10-Gold (for pUC57 plasmids), and Stbl3 or StellarComp (for pLVX-IRES-ZsGreen1, PiggyBac, and pAc/V5-His plasmids), grown in LB broth/agar plates containing the appropriate selective antibiotic (50 μ g/mL ampicillin or 100 μ g/mL kanamycin). Digestions were performed according to the relevant New England BioLabs online NEBcloner protocol. Digestion products were resolved using 1% agarose gel electrophoresis and bands excised for purification. DNA-containing gel fragments were purified using the GeneJET Gel Extraction kit (ThermoFisher) according to manufacturer’s instructions. Ligations were performed for two hours at room temperature using T4 DNA ligase (ThermoFisher). Final plasmids were purified using QIAprep Mini, Midi, or Maxi kits (QIAGEN) according to manufacturer’s instructions and stored at -20° C. Plasmid insertions were verified via Sanger sequencing using custom primers (IDT Technologies or Invitrogen) and the ABI PRISM 3730xl DNA Analyzer (Applied Biosystems) at the DNA Sequencing and Genotyping Core at Cincinnati Children’s Hospital Medical Center. Sequence files were aligned using Snappgene software and/or the online research platform Benchling (“Molecular Biology” tool). The 2nd generation CAR (PDL1-CD28-CD3 ζ) was designed by splicing the PD-L1 signal and extracellular domains (aa 1-238, NP_054862) to typical 2nd generation CAR domains^{14,51}, including the leader and hinge regions of CD8 α , CD28 transmembrane & intracellular domains, and CD3 ζ intracellular domain (Figure S1). The CAR sequence was synthesized by Genewiz into a pUC57 vector. The CAR construct was excised from pUC57 and ligated into the multiple cloning site (MCS) of the lentiviral vector pLVX-IRES-ZsGreen1 (Clontech). Clones were screened for the correct restriction digestion pattern and sequence-verified prior to being amplified and purified. The full length, human PD-1 protein sequence was obtained from UniProt (aa 1-288). An open reading frame (ORF) for this amino acid sequence was optimized for a *Drosophila* expression system using the “codon optimization tool” (IDT Technologies), then this DNA sequence was synthesized by Genewiz into a pUC57 plasmid. The PD-1 ORF was excised from pUC57 and ligated into the MCS of a pAc/V5-His A vector (Invitrogen), then verified via sequencing, amplified, and purified (referred to as “pAc/V5-His-PD1”). The human PD-1 ORF was excised from the aforementioned pUC57 plasmid and ligated into the MCS of a PiggyBac Transposon, Cloning and Expression Vector (System Biosciences, PB513B-1), then amplified, purified, and verified via sequencing (referred to as “PB513-PD1”).

Lentivirus generation and lentiviral transduction of NK-92 cells

After sequence verification the CAR-containing pLVX-IRES-ZsGreen plasmid was given to the Viral Vector Core at Cincinnati Children’s Hospital Medical Center where a lentivirus was packaged by transfection of HEK293T cells with a 3rd generation packaging system: pCDNA3.g/p.4xCTE plasmid (GagPol, 8 μ g/plate), pRSV rev plasmid (Rev, 6.5 μ g/plate), vector plasmid (8 μ g/plate), and m75-VSVG plasmid (VSV-G envelope, 2 μ g/plate). Viral supernatant from four 10-cm plates was collected 24-48 hours post-transfection, purified via sucrose-gradient, and titer analysis was performed by transfection of a control cell line and flow cytometry analysis. Viral supernatant was concentrated and stored at -80° C. NK-92 were transduced in 48 or 96-well flat bottom plates (Corning) that had been previously coated overnight with human fibronectin (Invitrogen) at 20 μ g/mL. Cells were transduced with either CAR-containing pLVX-IRES-ZsGreen lentiviral vector or an empty-vector control lentivirus at a multiplicity of infection of 5 in the presence of 8 μ g/mL protamine sulfate (added to culture media) for 4-6 hours at 37 $^{\circ}$ C. After thorough washing and growth for 48 hours, cells were sorted based on fluorescent reporter expression (Figure S2).

Generation of PD-1-expressing target cell lines

S2 cells were chemically-transfected using calcium chloride and the DES Blastocidin Support Kit (Invitrogen). Briefly, the pAc/V5-His-PD1 plasmid (or empty-vector control plasmid) was introduced at a ratio of $\geq 19:1$ to the pCoBlast plasmid vector (Invitrogen) in the presence of calcium chloride according to kit instructions. Cells were then cultured for a week in the presence of blasticidin to select for pCoBlast-expressing clones. Blastocidin-resistant cells transfected with pAc/V5-His-PD1 were stained for PD-1 expression as and sorted for PD-1⁺ cells (Figure S4A). Following > 2 weeks of culture, a portion of PD-1⁺ S2 cells were stained for PD-1 expression and further sorted into “PD-1^{Hi}” and “PD-1^{Lo}” populations (Figure S4A). All sorted S2 cells were cultured for > 2 weeks prior to co-culture with NK-92 to minimize any effects of residual anti-PD-1 antibody still bound to S2 cell surfaces. Raji cells were co-transfected via electroporation with either the empty PiggyBac plasmid (PB513) or PB513-PD1 in addition to the Super PiggyBac transposase plasmid (System Biosciences, PB210PA-1) at a 1:2.5 ratio using the Neon Transfection System (Invitrogen, MPK5000) at the following parameters: 1300v, 30ms, 1 pulse, and 7x10⁶ cells/mL. Electroporation parameters and cell concentration were obtained from the Neon Transfection System standard protocol for Raji cells (using 100 μ L tips). Transfected Raji cells were cultured in 6-well, low adherent plates prior to fluorescent sorting (Figure S4C) and subsequent selective culturing in the presence of puromycin.

qPCR

NK-92 total RNA was extracted using the RNeasy Mini Kit (QIAGEN) according to the manufacturer's protocol. Reverse transcription was performed using iScript Reverse Transcriptase and iScript Reaction mix per iScript cDNA Synthesis Kit manufacturer's protocol (Bio-Rad). Real-Time PCR reactions were carried out using a PrimeTime Gene Expression Master Mix and custom PrimeTime Std qPCR assay primer/probe sets (IDT Technologies), as well as a TaqMan Gene Expression Assay (ThermoFisher). An ABI 7500 Real-Time PCR Thermal Cycler (ThermoFisher) was used under the PCR polymerase activation and amplification conditions of 95°C for 3 minutes and 40 cycles (95°C for 15 s and 60°C for 1 minute).

Plate-bound activation assays

rhPD-1-Fc, anti-PD-L1, IgG1-Fc, and Goat IgG (R&D systems) were solubilized in PBS and added at varying concentrations in 100 μ L/well to 96-well MaxiSorp plates (ThermoFisher) before overnight incubation at 4°C. Plates were washed with PBS before counted NK-92 cells were added at a concentration of 4×10^4 cells/mL in 200 μ L per well in NK-92 media and incubated for 4 hours at 37°C. Degranulation was measured via addition of 2 μ g/mL of anti-CD107a (Biolegend) for the duration of the assay. PMA and ionomycin were added to positive control wells at 0.5 μ g/mL and 1 μ g/mL, respectively, for the duration of the assay.

NK-92 co-culture activation and cytotoxicity assays

For NK-92:S2 co-culture assays, NK-92 and S2 cells were combined at a ratio of 1:5 (2×10^4 and 1×10^5 , respectively) in 200 μ L of S2 media (without blasticidin) in 96-well round-bottom plates (Corning), then incubated at room temperature for 4 hours prior to analysis. For NK-92:Raji co-culture assays, NK-92 and Raji cells were combined at either a ratio of 1:5 (2×10^5 and 1×10^5 , respectively) to assess degranulation, or a ratio of 20:1 (2×10^5 and 1×10^4 , respectively) to assess killing. Assays were carried out in 200 μ L of Raji media (without puromycin) in 96-well round-bottom plates, then incubated at 37°C for 4 hours prior to analysis. For NK-92:CD4 co-culture assays, CD4 T cells were isolated from human tonsil cells by negative magnetic selection using the EasySep Human CD4+ T Cell Isolation Kit (StemCell Technologies) according to manufacturer's instructions, achieving 88% purity, on average (data not shown). This isolated CD4 fraction was counted and cultured in 96 well round-bottom plates at 30,000 cells/well in 100 μ L of cRPMI. 1.5×10^5 control or CAR NK-92 were added in 100 μ L cRPMI to each well for a 5:1 ratio of NK:T cells, whereas control wells received 100 μ L of cRPMI alone. Cells were then co-cultured for 4 hours in a 37°C incubator prior to collection and analysis. For NK-92:T_{FH}:B cell co-culture assays, human tonsil cells were subjected to negative magnetic selection using either the EasySep Human CD4+ T Cell Isolation Kit or the EasySep Human B Cell Isolation Kit (StemCell Technologies) according to manufacturer's instructions, achieving > 80% purity (data not shown). The isolated CD4 T cell fraction was stained with fluorescently conjugated antibodies to identify and sort for live (Zombie⁻) CD3⁺ CD4⁺ CXCR5⁺ T_{FH} cells. Similarly, isolated and stained B cells were sorted to obtain live (Zombie⁻) CD3⁺ C19⁺ CD27⁺ memory B cells. Sorted T_{FH} and B cells were cultured separately overnight (in a 37°C incubator) in 96 well round-bottom plates at 3×10^4 cells/well and 6×10^4 cells/well, respectively, in 100 μ L of cRPMI containing 1 μ g/mL staph enterotoxin B (EMD Millipore). The next day, each well of T_{FH} cells was combined with a single well of memory B cells (achieving a 1:2 ratio of T:B cells) and further cultured at 37°C. At days 3-4 post initial cell culture, 1.5×10^5 control or CAR NK-92 cells were added in 50 μ L cRPMI to each well to achieve a 5:1 ratio of NK:T_{FH} cells, whereas control wells received 50 μ L of cRPMI alone. Co-cultures were then incubated at 37°C for 4 hours (for measurements of degranulation and target cell lysis/viability) or 24 hours (for measurements of B cell proliferation and supernatant IgG) prior to collection and analysis. For calcein AM release assays, the sorted T_{FH} and CD27⁺ B cell co-cultures (at a 1:2 T:B ratio; previously stimulated with SEB for 4 days as described above) were labeled with a 1:300 dilution (volume:volume) of 1 mg/mL Calcein AM solution as established in a published protocol⁵². Labeled cells were transferred to 96 well round-bottom plates at 1×10^4 cells/well in 100 μ L cRPMI. Control or CAR NK-92 were added in 100 μ L cRPMI to wells at varying E:T ratios, whereas control wells received 100 μ L of cRPMI alone. These co-cultures were carried out for 4 hours at 37°C prior to collection and analysis. When measured, degranulation was assessed by addition of 2 μ g/mL of anti-CD107a PE-Cy7 (Biolegend) for the duration of the assay. When used, PMA and ionomycin were added at 0.5 μ g/mL and 1 μ g/mL, respectively, for the duration of the assay. When measured, propidium iodide (Biolegend) was added at a 1:10 ratio (volume:volume) directly to stained, unfixed cells approximately 10-15 minutes prior to flow cytometric acquisition. When measured, supernatant IgG was assessed using a human total IgG ELISA kit (eBioscience) according to manufacturer's instructions.

Evaluating CAR NK-92 function in humanized mice

Eight-week-old male and female NSGS mice were conditioned via a single i.p. injection of 30 mg/kg busulfan (Sigma Aldrich). Within 24 hours of collection, anticoagulated human cord blood was subjected to ficoll-gradient separation as described above. PBMC isolated from the interphase were washed with PBS and incubated with anti-human CD3 antibody (clone OKT-3; BioXCell) at 1 μ g antibody per 10^6 cells for 30 minutes on ice. As demonstrated elsewhere⁵³, the purpose of this step was to subsequently deplete human T cells following cord blood injection, thus preventing xenogeneic graft-versus-host disease and improving xeno-engraftment. Twenty-four hours after busulfan conditioning, mice were humanized via i.v. injection of 10-15 million (anti-CD3-treated) human cord blood leukocytes and the hematopoietic compartment was provided time to reconstitute by letting mice rest for 4-5 weeks. Mice were then given an intraperitoneal injection of 0.5 mL pristane (Sigma Aldrich) to induce an SLE-like inflammatory state as previously demonstrated²⁹. One week later, an initial dose of 10^7 irradiated (10 Gy, γ -ray) control or CAR-expressing NK-92 cells in PBS were injected intravenously into each mouse. Identical subsequent injections of NK-92 cells occurred once per week for three to five

weeks prior to carbon dioxide-induced euthanasia and tissue collection. Blood was collected using a 1cc insulin syringe inserted into the inferior vena cava and transferred to SST Microtainer tubes (BD) for serum isolation via centrifugation at 13000 RPM for 2 minutes. Serum was analyzed for IgG was using a human total IgG ELISA kit (eBioscience) according to manufacturer's instructions. Mouse spleens were harvested into cold cRPMI, mechanically broken apart, and gently passed through 70 μ m nylon strainers to obtain single-cell suspensions. Red blood cells were lysed using ACK-lysis buffer (ThermoFisher), and remaining spleen leukocytes were enumerated, resuspended in FACS buffer, and stained for flow cytometric analysis as described above.

QUANTIFICATION AND STATISTICAL ANALYSIS

All statistical analysis was performed using GraphPad Prism 7. Data in Figures 2E, 3B, 4A, and 4C–4F were each analyzed via an unpaired, two-tailed, parametric Student's t test with a 95% confidence interval (due to normal distribution) with Welch's correction in Figure 3B due to observed heteroscedasticity. Due to comparisons across more than two conditions, data in Figures 2D, 2F, 3C, and 4D–4F were analyzed using ordinary one-way ANOVA. Data in Figures 2D and 2F were subjected to Tukey's multiple comparison test with a single pooled variance to compare each column to every other column. Data in Figures 4D–4F were subjected to Dunnett's multiple comparison test with a single pooled variance to compare each column to the "No NK-92" control column. One data point was excluded from Figure 3C ("CAR NK-92" group) due to identification as an outlier using ROUT method (Q = 1%). EC₅₀ of rhPD-1-Fc for PD-L1 CAR NK cells was determined using the GraphPad Prism analysis "Nonlinear Regression (curve fit): [Agonist] vs. response - Variable slope (four parameters)" as further described here: https://www.graphpad.com/guides/prism/7/curve-fitting/index.htm?REG_DR_stim_variable_2.htm. Other statistical details for each experiment can be found in figure legends, which include statistical tests used, exact n values, definition of center, dispersion and precision measures, and number of independent experiments.

DATA AND CODE AVAILABILITY

This study did not generate any unique datasets or code.